<i>Paenibacillus alvei MP1</i> as a Producer of the Proteinaceous Compound with Activity against Important Human Pathogens, Including <i>Staphylococcus aureus</i> and <i>Listeria monocytogenes</i>

An emerging need for new classes of antibiotics is, on the one hand, evident as antimicrobial resistance continues to rise. On the other hand, the awareness of the pros and cons of chemically synthesized compounds’ extensive use leads to a search for new metabolites in already known reservoirs. Prev...

Full description

Bibliographic Details
Main Authors: Magdalena Pajor, Zirui Ray Xiong, Randy W. Worobo, Piotr Szweda
Format: Article
Language:English
Published: MDPI AG 2020-04-01
Series:Pathogens
Subjects:
Online Access:https://www.mdpi.com/2076-0817/9/5/319
Description
Summary:An emerging need for new classes of antibiotics is, on the one hand, evident as antimicrobial resistance continues to rise. On the other hand, the awareness of the pros and cons of chemically synthesized compounds’ extensive use leads to a search for new metabolites in already known reservoirs. Previous research showed that <i>Paenibacillus</i> strain (<i>P. alvei</i> MP1) recovered from a buckwheat honey sample presented a wide spectrum of antimicrobial activity against both Gram-positive and Gram-negative pathogens. Recent investigation has confirmed that <i>P. alvei</i> MP1 (deposited at DDBJ/ENA/GenBank under the accession WSQB00000000) produces a proteinaceous, heat-stable compound(s) with the maximum antimicrobial production obtained after 18 h of <i>P. alvei</i> MP1 growth in LB medium at 37 °C with continuous shaking at 200 RPM. The highest activity was found in the 40% ammonium sulfate precipitate, with high activity also remaining in the 50% and 60% ammonium sulfate precipitates. Moderate to high antimicrobial activity that is insensitive to proteases or heat treatment, was confirmed against pathogenic bacteria that included <i>L. monocytogenes</i> FSL – X1-0001 (strain 10403S), <i>S. aureus</i> L1 – 0030 and <i>E. coli</i> O157: H7. Further studies, including de novo sequencing of peptides by mass spectrometry, are in progress.
ISSN:2076-0817